Vidyya Medical News Service
*
Volume 5 Issue 265 Published - 14:00 UTC 08:00 EST 22-Sep-2003 Next Update - 14:00 UTC 08:00 EST 23-Sep-2003
little clear gif used for spacer
.
*

Study shows state tobacco control programs cut cigarette sales
A landmark new study finds that cigarette sales dropped more than twice as much in states that spend more on comprehensive tobacco control programs than in the United States as a whole. Between 1990 and 2000, sales fell an average of 43 percent in four key states with large program expenditures Arizona, California, Massachusetts, and Oregon compared with 20 percent for all states. Program funding levels accounted for a substantial portion of this difference, with increasing expenditures producing bigger and faster declines in sales. more

*
Tools for physicians: Relief of viral illness (no antibiotics necessary) prescription pads
This "prescription" pad is actually a checklist for the doctor to describe symptomatic relief for viral illnesses.  more

 


*
Boosted Saquinavir shows significant safety benefit over boosted Crixivan(R) in large head-to head study of hiv protease inhibitors
Clinical study results published in the Sept. 1 issue of The Journal of Infectious Diseases show that boosted saquinavir (saquinavir 1000 mg with ritonavir 100 mg) reduced HIV to undetectable levels in significantly more patients than boosted Crixivan(R) (indinavir 800 mg with ritonavir 100 mg) at 48 weeks, as a result of a higher discontinuation rate in the indinavir arm due to adverse events.  more

*
Prescribing information: Fortovase(R) (saquinavir soft gel capsules)
The most frequently reported adverse events at least possibly related to treatment with Fortovase and of at least moderate intensity -- observed in trials evaluating the approved 1200 mg three-times-daily dosing regimen -- include nausea (17.8 percent), diarrhea (15.6 percent), abdominal discomfort (13.3 percent) and dyspepsia (8.9 percent).  more

*
High tumor response rate in first-line treatment of advanced breast cancer
A study published in the September 2003 issue of Annals of Oncology (vol. 14, issue 9) indicated that exemestane demonstrates a high response rate for first-line treatment of advanced breast cancer in postmenopausal women. Response rate is a measurement of how effective the treatments are in shrinking the tumor.  more

 
little clear gif used for a space